August 2024
Alaskans Can Virtually Manage Diabetes Risk for Free with Omada Health
Omada Health, Diabetes Management, Virtual Chronic Care, Alaska, Free Program
US Lawmakers Demand FDA Probe into Clinical Trials Linked to China’s Military
FDA investigation, clinical trials, China’s military, US lawmakers, bipartisan scrutiny
Bayer Pharma’s Overhaul Not Slowing Down Deal Making, Says BD Chief
Bayer Pharma, deal making, group overhaul, biotech, pharmaceutical industry
Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Jynneos, Global Health Emergency, Africa CDC, WHO
FTC Supports FDA’s Simplified Biosimilar Interchangeability Plan
biosimilars, interchangeable biosimilars, FDA, FTC, pharmaceutical competition, drug pricing
Merck & Co. Expands Oncology Pipeline with Kelun-Biotech ADCs
Merck & Co., Kelun-Biotech, Antibody-Drug Conjugates (ADCs), Cancer Treatment, Oncology Pipeline
Lilly’s Tirzepatide Demonstrates Significant Reduction in Diabetes Risk and Sustained Weight Loss in Overweight Adults
tirzepatide, diabetes risk reduction, sustained weight loss, overweight adults, pre-diabetes, obesity, Eli Lilly, Mounjaro, Zepbound
Liquidia’s Yutrepia Receives Tentative FDA Approval Due to Tyvaso Exclusivity
Liquidia, Yutrepia, FDA, tentative approval, Tyvaso, exclusivity, pulmonary arterial hypertension, PAH, PH-ILD
J&J’s Rybrevant Combination Approved for First-Line Treatment of EGFR-Mutated Non-Small Cell Lung Cancer
Rybrevant, Johnson & Johnson, FDA approval, non-small cell lung cancer, EGFR mutations, lazertinib, chemotherapy-free regimen
Navigating Challenges and Opportunities in the 2024 Life Sciences Industry Outlook
Life Sciences Industry, 2024 Outlook, Biotechnology, Medical Devices, Artificial Intelligence, Drug Pricing, Regulatory Changes, Supply Chain Security, Talent Shortage